Kornimate/medical-research-clean huggingface dataset:
effects of lymphatic drainage on axillary web syndrome

Conditions: Axillary Web Syndrome

Summary: axillary web syndrome (aws) is a common condition related to cording in axilla as a result of axillary lymph nodes dissection surgery in breast cancer patients. this condition comprises of 86% population who underwent breast cancer surgery, but this condition is usually under diagnosed. usually characterized by pain full cording of soft tissue and contractures at axillary region. this study aims to see the effects of manual lymphatic drainage with or without soft tissue mobilization on patients with axillary web syndrome. it will be a randomized control trial which will be conducted in cancer centers in government sector hospitals. 30 participants will be enrolled by non probability sampling technique through lottery method into two groups, 15 participants in each group. one group will receive manual lymphatic drainage, while other group will receive manual lymphatic drainage in addition to soft tissue mobilization (3-5 treatment sessions per week for 4 weeks). base line treatment regimen include stretching, range of motion and strengthening exercises. for outcome measures treatment will be assessed on questionnaires including disabilities of arm shoulder and hand questionnaire (dash), numeric pain rating scale (nrs), breast cancer specific qol questionnaires (eortc qlq-c30, eortc qlq br-23), patient specific functional scale (psfs), goniometer and dynamometer.


Eligibility criteria:
inclusion criteria: * breast cancer patients with pain over \&gt;3 points, 4 weeks after surgery using * numeric pain rating scale on upper limb. * with visible and palpable cords in axilla, arm and breast after surgery. exclusion criteria: * acute thrombosis, musculoskeletal disorders,skin * problems: infections, osteoarthritis, rheumatoid arthritis, rotator cuff syndrome, adhesive capsulitis, * any other injury, trauma and * any other surgery.

Keywords: axillary web syndrome manual lymphatic drainage
evaluation of an internet-based intervention for hazardous drinkers

Conditions: Hazardous Alcohol Consumption

Summary: the purpose of this study is to determine whether the investigators internet-based intervention is effective to help hazardous drinkers reducing their alcohol consumption.


Eligibility criteria:
inclusion criteria: * alcohol use disorders identification test (audit) score from 6 (female) or 7 (male) to 12
real-time early detection of nephrotoxicity by urinary biomarker analysis with seroflow technology

Conditions: Acute Kidney Injury

Summary: the study aims to perform real-time validation of the renafast kit (a point-of-care test kit that quantifies three urinary proteins) in predicting acute kidney injury(aki) among patients prescribed drug therapies of nephrotoxic potential. based on the type and duration of drug therapy, a maximum of 5 time-point urine samples will be collected from consenting patients and a real-time biomarker analysis will be conducted using the renafast kits.

all eligible patients who fulfill the inclusion and exclusion criteria will be approached for consent. the patients with the highest aki risk (with all 3 urine biomarkers, clusterin, monocyte chemoattractant protein-1 (mcp1), and beta-2 microglobulin (ß2mg), above prediction threshold set by the study) will be identified. the nephrology consultants within the research team will perform a medical chart and physical review(where required) of these patients, noting potential actions to be taken in data collection forms. this will help in evaluating if indeed there are perceived interventions that could potentially be delivered in response to early prediction of aki.

Eligibility criteria:
inclusion criteria: * patients who receive a projected ≥7 days of therapy of antimicrobials including aminoglycosides (i.e., gentamicin or amikacin), vancomycin, polymyxin, amphotericin and foscarnet. * patients who receive a projected ≥7 days of calcineurin inhibitors (cyclosporin, tacrolimus) * patients who receive a projected ≥7 days of anti-virals (cidofovir and ganciclovir) * patients who receive anti-cancer drugs (chemotherapy such as cisplatin, ifosfamide, methotrexate, pemetrexed) or * patients who receive anti-cancer drugs (immunotherapy such as immune checkpoint inhibitors as well as types of vgef inhibitors that are associated with acute kidney injury) exclusion criteria: * patients with aki prior to therapy initiation. * patients with baseline egfr \< 15 ml/min/1.73m2 (stage 5 chronic kidney disease) * patients admitted to intensive care unit at study baseline, as critical illness is a natural confounder to aki * females who are pregnant * immediate post-kidney transplant recipients (initial 3 months following transplant).

Keywords: nephrotoxicity urinary biomarkers clusterin monocyte chemoattractant protein-1 (mcp1) beta-2 microglobulin (ß2mg) anti-microbials calcineurin inhibitors
circulating tumor cells in patients with locally advanced rectal cancer

Conditions: Locally Advanced Rectal Adenocarcinoma; Metastatic Rectal Adenocarcinoma; Rectosigmoid Adenocarcinoma; Recurrent Rectal Adenocarcinoma; Recurrent Rectosigmoid Carcinoma; Stage III Rectal Cancer AJCC v8; Stage IIIA Rectal Cancer AJCC v8; Stage IIIB Rectal Cancer AJCC v8; Stage IIIC Rectal Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8; Stage IVA Rectal Cancer AJCC v8; Stage IVB Rectal Cancer AJCC v8; Stage IVC Rectal Cancer AJCC v8

Summary: this study looks at the level of circulating tumor elements (cancer cells or dna pieces floating in the blood) and how it may be related to how the tumor responds to standard treatment in patients with rectal cancer that has spread to nearby tissue or lymph nodes (locally advanced). researchers will also compare the level and genetic characteristics of circulating tumor elements between individuals with rectal cancer and healthy individuals to understand how they may change over time. information from this study may help researchers better understand rectal cancer.

primary objectives: i. to establish the rate of circulating tumor elements (cte), including but not limited to circulating tumor cells and circulating tumor deoxyribonucleic acid (dna) detection in patients with locally advanced rectal cancer (larc), relative to other stages. ii. to assess changes in detected ctes associated with neoadjuvant therapy in patients with larc. iii. to correlate ctes with neoadjuvant treatment response as an indicator of disease risk. outline: patients and healthy participants undergo collection of blood sample at baseline. patients may also undergo collection of blood sample collections during tumor surgery, 4 weeks after surgery or after completion of treatment if you are not surgery, 8 weeks after the last dose of chemotherapy, 1 year after surgery or 1 year after completion of treatment if not having surgery, 2 years after surgery or 2 years after completion of treatment if not having surgery, and within 6 years after treatment or at the end of the 6 year follow-up if the disease gets worse with treatment or comes back.

Eligibility criteria:
inclusion criteria: * healthy subject: no known diagnosis of colorectal cancer (crc) or any other type of cancer for the last 10 years.(basal cell skin cancer is allowed). subjects will be asked about their cancer history and a verbal confirmation is required * any patient with diagnosis of rectal (or rectosigmoid) adenocarcinoma, including: * patients with primary disease with or without neoadjuvant therapy; or * patients with recurrent disease with or without neoadjuvant therapy; or * patients with metastatic disease with or without prior treatment * no known current diagnosis of other invasive cancer; if prior diagnosis of other cancer, he/she has been free from cancer for \>= 3 years and is on no active treatment * adequate mental and language capacity to provide consent
esm pilot: mobile phones and psychology

Conditions: Communication; Addiction; Affect

Summary: the research team will investigate whether there is a relation between smartphone usage and psychological parameters using the smartphone application.

there are indications for mobile phone effects on psychological and psychological functioning. most publications on this subject report effects on 'mobile phone addiction'. a methodological problem in these studies is the collection of data in retrospect. with the mobile phone application it is possible to prevent this type of bias. by collecting real-life data in a longitudinal design with a 2 x n=1 pilot study, it is possible to obtain an impression of the relationship between mobile phone usage and emotion/behavior efficiently. the objective of this study is to investigate whether there is a relation between smartphone usage and psychological parameters in young adults. taking into accordance the type of research (observational) and the present state of literature (the relationship between mobile phones and psychological effects has not been studied before using the experience sampling method (e.s.m.)) the following hypothesis are formulated. it is expected that the undesired absence of one's phone will lead to an enlarged stress level. furthermore, it is expected that an increase of phone usage will lead to more depressive symptoms, to less concentration and to sleep disturbance. finally, it is expected that loneliness will lead to increased phone usage. a longitudinal pilot study, in which the participant will be asked to fill out the mobile phone application questionnaire 10 times a day at random moments on a smartphone, during a 3 months period. the mobile phone application questionnaire contains a series of multiple choice questions about the present affect (three positive, five negative), the present context and activities (physical activity, occupation, presence of other people), physical discomfort (fatigue, concentration level, pain) and mobile phone usage (frequency, frustration when unable to use phone) since the last beep. positive affect: cheerful, mentally fit and relaxed. negative affect: irritated, bored, lonely, stressed and worrying. the answers will be registered using a 7-point likert scale, ranging from 'not' to 'very'. participants will be invited to the research location twice for a briefing (30 minutes) and a debriefing session (30 minutes). furthermore the participants will be asked to fill out the mobile phone application questionnaire on a daily base after every beep. it is expected this will cost a time investment of approximately 15 minutes per day. the questionnaires are generally experienced as a small burden (in previous research performed by this department). participation is not associated with health risks.

Eligibility criteria:
inclusion criteria: * healthy * good understanding of dutch language * smartphone user exclusion criteria: * psychiatric diagnosis * pregnancy

Keywords: experience sampling method
observational study evaluating the effectiveness of drug concentration to predict the recapture of response in crohn's disease patients with loss of response ( prada )

Conditions: Crohn's Disease

Summary: this is a multi-center study that explores the relationship between recapture of response with escalation to weekly adalimumab and trough adalimumab concentration before escalation in patients experiencing lack of response (lor).


Eligibility criteria:
inclusion criteria: * documented diagnosis of crohn's disease. * treatment with adalimumab, for a minimum of 16 weeks, as per clinical practice, at a dose of 160 mg at week 0, 80 mg at week 2, and then 40 mg q2w with a documented response as defined by the investigator. * current evidence of active inflammatory disease/lor defined as the presence of active inflammation (confirmed with a crp ≥ 5 mg/l and/or a fecal calprotectin ≥ 250µg/g. * ability of subject to participate fully in all aspects of this clinical trial. * written informed consent must be obtained and documented. exclusion criteria: * primary non-responders to 16 weeks of adalimumab therapy. * received any investigational drug within the 16 weeks of adalimumab therapy. * serious underlying disease other than cd that, in the opinion of the investigator, may interfere with the subject's ability to participate fully in the study. * history of alcohol or drug abuse that, in the opinion of the investigator, may interfere with the subject's ability to comply with the study procedures. * stools positive for clostridium difficile. * pregnant or lactating women. * current enrolment in any other interventional research study. * presence of perianal or abdominal abscess.

Keywords: patient reported outcome 2 (pro 2) c-reactive protein (crp) adalimumab harvey bradshaw index (hbi) therapeutic drug monitoring (tdm) anti-adalimumab antibody (aaa)
acute cardio-metabolic responses to montmorency tart cherry supplementation in metabolic syndrome patients

Conditions: Metabolic Syndrome; Insulin Resistance; Hypertension

Summary: the present study examined the effect of montmorency tart cherry juice and capsules on functional and blood-based cardio-metabolic markers in humans with metabolic syndrome. participants received a single bolus of montmorency tart cherry juice, montmorency tart cherry capsules and placebo in a random, crossover trial. outcome variables were measured immediately pre- and up to 5 hours post-bolus. it was hypothesised that montmorency tart cherry juice and capsules would improve cardio-metabolic markers. furthermore, it was hypothesised that montmorency tart cherry capsules would be more beneficial than montmorency tart cherry juice due to increased bioavailability of phytochemicals.


Eligibility criteria:
inclusion criteria: * non-smoker, meet 3 of 5 criteria for metabolic syndrome based on national cholesterol education program-adult treatment panel iii guidelines: 1. waist circumference: \>102cm (men), \>88cm (women) 2. fasting serum triglycerides: ≥1.69 mmol.l-1 3. fasting high density lipoprotein: \<1.03 mmol.l-1 (men), \<1.29 mmol.l-1 (women) 4. blood pressure: ≥130 mmhg sbp or ≥85 mmhg dbp 5. fasting plasma glucose: ≥6.1 mmol.l-1 exclusion criteria: * current or previous history of gastrointestinal, cardiovascular, hepatic or renal disease, currently diagnosed with diabetes or uncontrolled hypertension (≥160/100 mmhg), allergy to maltodextrin or specific fruit products and those currently taking medication (such as steroids, nsaids, antibiotics, antihypertensive, hypoglycaemic, lipid-lowering drugs) or currently using any nutritional or antioxidant supplement. heavy alcohol consumption (\>14 units per week).

Keywords: montmorency tart cherry anthocyanins polyphenols metabolic syndrome insulin resistance hypertension lipid profile
safety and efficacy of mobic inj. (meloxicam) for the patients with oa or ra: observational study

Conditions: Osteoarthritis; Arthritis, Rheumatoid

Summary: the main objective of this pms study was to monitor and assess the safety of mobic® intramuscular injection (7.5mg \~ 15mg, q.d.) up to 3 days (in case of need for prolonged treatment, switch to mobic® capsule therapy was possible) in korean patients with osteoarthritis and rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: diagnosed as osteoarthritis and rheumatoid arthritis exclusion criteria: 1. known hypersensitivity to meloxicam 2. cross hypersensitivity to aspirin and other non-steroidal anti-inflammatory drugs 3. symptoms of asthma, rhinitis, angioneurotic edema, or urticaria following the administration of aspirin or other nsaids 4. active peptic ulceration 5. severe hepatic failure. 6. non-dialysed severe renal insufficiency 7. children and adolescents aged 15 years or less 8. pregnancy or breastfeeding
study to investigate the optimal dose of org 36286 to induce monofollicular ovulation in women with who group ii anovulatory infertility (p07016)

Conditions: Infertility

Summary: the objectives of this trial were to investigate the feasibility and the optimal dose of a single administration of org 36286 to induce monofollicular ovulation in women with who group ii anovulatory infertility and to assess the safety (including the absence of antibody formation) of org 36286.

this was a phase ii, randomized, double-blind, placebo controlled, comparative trial to investigate the optimal dose of a single administration of org 36286 to induce monofollicular ovulation in women with who group ii anovulatory infertility. treatment injection was given on day 1-3 after the onset of a spontaneous or progestagen induced withdrawal bleeding. after injection, ultrasound monitoring and sampling for serum hormones were done on treatment days 3, 5, and daily from day 7 to 21 or until a urinary luteinizing hormone (lh) peak was detected. from treatment day 7 the urinary lh response was assessed to detect the preovulatory lh peak. in case of hyperstimulation, production of endogenous gonadotropins could be suppressed by giving daily injections of gnrh antagonist. post-treatment assessments were done in the third week after the urinary lh peak. if no lh peak was detected, posttreatment assessments were performed four to five weeks after org 36286 or placebo injection.

Eligibility criteria:
inclusion criteria: * wish to conceive; * oligomenorrhea (cycle length \>=41 days) or amenorrhea (no menstrual cycle for \>6 months); * body mass index (bmi) \>=18 and \<=32 kg/m\^2; * serum fsh levels within normal limits (1-10 iu/l); * normal serum prolactin and thyroid stimulating hormone (tsh) levels; * progestagen induced withdrawal bleeding or spontaneous menstrual bleeding; exclusion criteria: * tumours of the ovary, breast, uterus, pituitary or hypothalamus; * pregnancy or lactation; * undiagnosed vaginal bleeding; * ovarian cysts or enlarged ovaries not related to polycystic ovarian disease (pcod); * any ovarian and/or abdominal abnormality interfering with ultrasound examination; * malformations of the sexual organs incompatible with pregnancy; * clomiphene resistance with documented anovulation (treated with 150 mg clomiphene for five days and no ovulation); * treatment with metformin, gonadotropins, or gnrh analogs within 90 days prior to the start of org 36286 treatment; * treatment with clomiphene citrate within 42 days prior to the start of org 36286 treatment; * alcohol or drug abuse within the 12 months preceding signing of informed consent; * any clinically relevant abnormal laboratory value; * hypersensitivity to any of the substances in org 36286; * hypersensitivity to orgalutran® or any of its components; * use of any investigational drugs during 90 days before screening or previous participation in this trial.

Keywords: ovulation induction pharmacological effects of drugs hormones hormone substitutes and hormone antagonists pharmacological actions randomized multi-center multi-national
mri morphology of femoral notch in acl injury

Conditions: ACL Injury

Summary: this study aims to investigate the association between femoral notch morphology, as assessed by mri, and the risk of acl injury


Eligibility criteria:
inclusion criteria: * patient aged 18-50 years. * diagnosed with an acl injury and confirmed by mri and age-matched controls. exclusion criteria: * age \ 50 years * patients with previous knee surgeries * congenital knee deformities * systemic conditions affecting bone health

Keywords: acl ,femoral notch
dec+flu+bu conditioning regimen for elderly aml in cr undergoing allo-hsct

Conditions: Acute Myeloid Leukemia; Allogeneic Hematopoietic Stem Cell Transplantation; Conditioning; Elderly

Summary: allogeneic hematopoietic stem cell transplantation (allo-hsct) is reported to be able to improve the outcomes for elderly acute myeloid leukemia (aml) in complete remission (cr). at present, the best conditioning regimen for elderly aml in cr remains in discussion. in this prospective study, the safety and efficacy of dec+flu+bu myeloablative conditioning regimens in patients with elderly aml in cr undergoing allo-hsct are evaluated.

allogeneic hematopoietic stem cell transplantation (allo-hsct) is reported to be able to improve the outcomes for elderly aml(older than 60 years) in complete remission (cr). at present, the best conditioning regimen for elderly aml in cr remains in discussion. flu+bu conditioning regimen is the most commonly used regimen for elderly aml in cr undergoing allo-hsct. however, it appears to have higher relapse rate. to reduce the relapse rate, decitabine is added in the conditioning regimen. in this prospective study, the safety and efficacy of decitabine+ fludarabine+busulfan myeloablative conditioning regimens in patients with elderly aml in cr undergoing allo-hsct are evaluated.

Eligibility criteria:
inclusion criteria: * aml patients older than 60 years, younger than 80 years * in complete remission before transplantation * with hla-matched sibling donors exclusion criteria: * any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure) * patients with any conditions not suitable for the trial (investigators' decision)
radiomics and molecular classification in endometrial cancer

Conditions: Endometrial Cancer; Uterine Cancer; Endometrium Tumor

Summary: molecular/genomic profiling is the most accurate method to assess the prognosis of endometrial cancer patients. interestingly, the adoption of radiomics showed important results, across various oncologic specialties. radiomic allows extracting mineable high-dimensional data from clinical images, thus providing a number of noteworthy information of the tumor tissues. we aim to correlate radiomic features obtained from ultrasound images with the molecular/genomic profiling to identify new hallmarks for stratification of endometrial cancer patients into different classes of risk the central hypothesis is that combining radiomic features might allow identifying various classes of risk for endometrial cancer. the rationale for the proposed research is that once validated, radiomics applied to ultrasonographic images would be an effective, innovative, and cheap method for tailor operative and postoperative treatment modality in endometrial cancer.


Eligibility criteria:
inclusion criteria: (i) preoperative endometrial cancer (any histology); (ii) preoperative ultrasonographic examination; (iii) surgical treatment; (iv) age \>= 18 years; (v) signed informed consent for research purposes. exclusion criteria: (i) consent withdraw; (ii) lack of available (tumor) tissue for molecular/genomic profiling.

Keywords: radiomics endometrial cancer molecular/genetic profiling radiogenomics ultrasound